The Connection Between Mitochondria and SASP: Why Senolytic Drugs Work for Some and Not Others

Senolytic drugs are a huge promise in anti-aging medicine. They promise to "kill only the zombie cells," leaving healthy cells intact. In experiments on old mice, they rejuvenated the body, strengthened the immune system, and improved life. In human trials, the results are more mixed. Why? New research published in Cell Death Discovery offers a surprising answer: The state of the mitochondria in zombie cells determines whether they live or die.

What are Senolytic Drugs?

Senolytics are a family of drugs aimed at killing senescent cells (cellular senescence) - cells that have stopped dividing with age but also do not die, and continue to secrete pro-inflammatory substances that damage surrounding tissues. They are called "zombie cells."

The first senolytic was a combination of Dasatinib + Quercetin (D+Q) reported in 2015. Since then, a long list has developed: Navitoclax, Fisetin, ABT-737, FOXO4-DRI, and dozens more. The first clinical trial in humans was conducted in 2019, and dozens of trials are ongoing since.

The Problem: Not All Senolytics Work the Same

In clinical research, the results were confusing:

• Some patients showed dramatic improvement in lung function, muscle strength, and inflammatory markers
• Some showed nothing at all
• Some showed side effects of unexpected intensity

The researchers wondered: What is the difference? Same drug, similar dosage, similar age. Why did it clear 50% of senescent cells in one patient, and not even 5% in another?

The Discovery: Mitochondria Decide

The team investigated the question in the lab. They took different human senescent cells with varying degrees of mitochondrial activity and treated them with senolytics. The finding was clear:

"Zombie cells with more active mitochondria were more resistant to senolytics. Cells with damaged mitochondria were more vulnerable."

Mechanism explanation: Classic senolytics act on anti-apoptotic proteins (BCL-2, BCL-xL) and remove the cell's protection against programmed death. But if the mitochondria in the cell are strong and can activate alternative defense pathways (energy, production of rescue proteins), the cell can survive.

SASP: The Central Secretion

The team added another dimension: the SASP (Senescence-Associated Secretory Phenotype) - the inflammatory secretions released from zombie cells. They discovered that cells with a stronger SASP tended to repeat themselves:

• Strong SASP = more cytokine production = more energy required = mitochondria operating at high intensity
• Active mitochondria = resistance to senolytics
• These cells continue to live, continue to pollute the environment, and continue to cause damage

This is a negative vicious cycle. Precisely the most harmful zombie cells are the hardest to kill.

The Solution: A Two-Step Approach

The researchers propose a new strategy for 2030 and beyond:

1. First step: Weakening the mitochondria. Drugs that impair mitochondrial metabolism in zombie cells only (there are selective ways)
2. Second step: Classic senolytics. After the zombie cells are "stripped" of mitochondrial protection, classic senolytics work with much higher effectiveness

In mice, this approach cleared 3 times more zombie cells than senolytics alone.

Implications for Cancer

This connection is also important for cancer medicine. Since many cancer cells enter a state of senescence following chemotherapy (Therapy-Induced Senescence), they become vulnerable zombie cells. But if their mitochondria are active, they are resistant to senolytics. The two-step approach can help here too: eliminate zombie cancer cells not killed by chemotherapy.

What Does This Mean for Normal People?

The good news: If you are healthy and taking Fisetin or another senolytic supplement, the effect will not be the same for everyone. Your body, genetics, lifestyle, and mitochondrial state all influence it.

What can you do to help senolytics work better?

1. Improve mitochondria in healthy cells. High-intensity exercise, intermittent fasting, and CoQ10 - all support mitochondria
2. In general, a multimodal approach. Don't rely on just one senolytic supplement. Combine with exercise, sleep, and an anti-inflammatory diet
3. Timing. Senolytic supplements are more beneficial in a fasting state (active autophagy) than after a meal

Next Steps in the Clinic

The researchers are already recruiting patients for a clinical trial testing the two-step approach. The first trials are planned for 2027, with results expected in 2029.

Broader Message: There Is No "Magic Pill"

This discovery is an example of what happens with every anti-aging drug: The more we understand it, the more we see it is not uniform. The same drug, the same approach, can work wonderfully for one person and poorly for another. The reason: The human body is multidimensional. Anti-aging in the future will be personalized: based on your genome, your mitochondrial state, and additional tests, a unique protocol will be created for you.